Utilization patterns of antiepileptic drugs among adult epileptic patients at a tertiary hospital in Oman

International Journal of Pharmacy Practice

Volumn 21, Issue 2, 2013, Pages 117-122

  Al Za'Abi, Mohammed ^a   Ahmed, Rowayda ^a   Al Asmi, Abdullah ^b   Al Zakwani, Ibrahim ^a  

^a SULTAN QABOOS UNIVERSITY   (Oman)

^b SULTAN QABOOS UNIVERSITY HOSPITAL   (Oman)

Author keywords

antiepileptic drugs; epilepsy; therapeutic drug monitoring; utilization pattern

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLONAZEPAM; ETIRACETAM; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ADULT; AGED; ARTICLE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG UTILIZATION; EMERGENCY WARD; EPILEPSY; FEMALE; FOCAL EPILEPSY; FOLLOW UP; GENERALIZED EPILEPSY; HUMAN; INFORMATION PROCESSING; INSTITUTIONAL ETHICS; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; MYOCLONUS EPILEPSY; OMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TEMPORAL LOBE EPILEPSY; TERTIARY HEALTH CARE; UNIVERSITY HOSPITAL;

ADOLESCENT; ADULT; ANTICONVULSANTS; DRUG MONITORING; DRUG THERAPY, COMBINATION; EPILEPSY; FEMALE; HUMANS; MALE; MIDDLE AGED; OMAN; PHYSICIAN'S PRACTICE PATTERNS; TERTIARY CARE CENTERS;

EID: 84874697043     PISSN: 09617671     EISSN: 20427174     Source Type: Journal    
DOI: 10.1111/j.2042-7174.2012.00240.x     Document Type: Article

References (49)

1. Banerjee PN, et al. The descriptive epidemiology of epilepsy-a review. Epilepsy Res 2009; 85: 31-45.
2. Benamer HT, et al. A systematic review of the epidemiology of epilepsy in Arab countries. Epilepsia 2009; 50: 2301-2304.
3. Stafstrom CE,. Epilepsy: a review of selected clinical syndromes and advances in basic science. J Cereb Blood Flow Metab 2006; 26: 983-1004.
4. o 999, January 2009. Geneva: World Health Organization, 2009.
5. Benn EK, et al. Estimating the incidence of first unprovoked seizure and newly diagnosed epilepsy in the low-income urban community of Northern Manhattan, New York City. Epilepsia 2008; 49: 1431-1439.
6. McElroy-Cox C,. Alternative approaches to epilepsy treatment. Curr Neurol Neurosci Rep 2009; 9: 313-318.
7. Jobst B,. Brain stimulation for surgical epilepsy. Epilepsy Res 2010; 89: 154-161.
8. Boon P, et al. Electrical stimulation for the treatment of epilepsy. Neurother 2009; 6: 218-227.
9. Freeman J, et al. The ketogenic diet: from molecular mechanisms to clinical effects. Epilepsy Res 2006; 68: 145-180.
10. Kossoff EH, et al. Ketogenic diets: evidence for short- and long-term efficacy. Neurother 2009; 6: 406-414.
11. Beghi E,. Management of a first seizure. General conclusions and recommendations. Epilepsia 2008; 49 (Suppl. 1): 58-61.
12. Johannessen Landmark C, et al. Pharmacological management of epilepsy: recent advances and future prospects. Drugs 2008; 68: 1925-1939.
13. Vajda FJ,. Pharmacotherapy of epilepsy: new armamentarium, new issues. J Clin Neurosci 2007; 14: 813-823.
14. Boison D, et al. Therapeutic epilepsy research: from pharmacological rationale to focal adenosine augmentation. Biochem Pharmacol 2009; 78: 1428-1437.
15. Azar NJ, et al. Considerations in the choice of an antiepileptic drug in the treatment of epilepsy. Semin Neurol 2008; 28: 305-316.
16. Kwan P, et al. Effectiveness of first antiepileptic drug. Epilepsia 2001; 42: 1255-1260.
17. Kwan P, et al. Clinical trials of antiepileptic medications in newly diagnosed patients with epilepsy. Neurology 2003; 60 (11 Suppl. 4): S2-12.
18. Kwan P, et al. Drug treatment of epilepsy: when does it fail and how to optimize its use? CNS Spectr 2004; 9: 110-119.
19. Cretin B, et al. Adjunctive antiepileptic drugs in adult epilepsy: how the first add-on could be the last. Expert Opin Pharmacother 2010; 11: 1053-1067.
20. Kaminski RM, et al. Benefit of combination therapy in epilepsy: a review of the preclinical evidence with levetiracetam. Epilepsia 2009; 50: 387-397.
21. Perucca E,. Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age. Clin Pharmacokinet 2006; 45: 351-363.
22. Privitera MD, et al. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand 2003; 107: 165-175.
23. Sendrowski K, et al. New antiepileptic drugs-an overview. Rocz Akad Med Bialymst 2005; 50 (Suppl. 1): 96-98.
24. Zaccara G, et al. Comparison of the efficacy and tolerability of new antiepileptic drugs: what can we learn from long-term studies? Acta Neurol Scand 2006; 114: 157-168.
25. French JA, et al. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004; 62: 1252-1260.
26. Beghi E,. Efficacy and tolerability of the new antiepileptic drugs: comparison of two recent guidelines. Lancet Neurol 2004; 3: 618-621.
27. Hanssens Y, et al. Drug utilization pattern of anti-epileptic drugs: a pharmacoepidemiologic study in Oman. J Clin Pharm Ther 2002; 27: 357-364.
28. Forsgren L, et al. The epidemiology of epilepsy in Europe-a systematic review. Eur J Neurol 2005; 12: 245-253.
29. Beghi M, et al. Utilization and costs of antiepileptic drugs in the elderly: still an unsolved issue. Drugs Aging 2009; 26: 157-168.
30. ArulKumaran KSG, et al. A study on drug use evaluation of anti-epileptics at a multispecialty tertiary care teaching hospital. Int J PharTech Res 2009; 1: 1541-1547.
31. Moran NF, et al. Epilepsy in the United Kingdom: seizure frequency and severity, anti-epileptic drug utilization and impact on life in 1652 people with epilepsy. Seizure 2004; 13: 425-433.
32. Rochat P, et al. Antiepileptic drug utilization: a Danish prescription database analysis. Acta Neurol Scand 2001; 104: 6-11.
33. Ministry of National Economy. Facts & Figures 2009. Muscat: Sultanate of Oman, June 2010.
34. Glauser T, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006; 47: 1094-1120.
35. Czapinski P, et al. Mechanisms of action of antiepileptic drugs. Curr Top Med Chem 2005; 5: 3-14.
36. Hollingworth SA, et al. Antiepileptic drugs in Australia: 2002-2007. Pharmacoepidemiol Drug Saf 2010; 19: 82-89.
37. Johannessen Landmark C, et al. Antiepileptic drugs in epilepsy and other disorders-a population-based study of prescriptions. Epilepsy Res 2009; 87: 31-39.
38. Alacqua M, et al. Newer and older antiepileptic drug use in Southern Italy: a population-based study during the years 2003-2005. Epilepsy Res 2009; 85: 107-113.
39. Kwan P, et al. Combination therapy in epilepsy: when and what to use. Drugs 2006; 66: 1817-1829.
40. Faught E,. Monotherapy in adults and elderly persons. Neurology 2007; 69 (24 Suppl. 3): S3-S9.
41. Hsieh LP, et al. Antiepileptic drug utilization in Taiwan: analysis of prescription using National Health Insurance database. Epilepsy Res 2009; 84: 21-27.
42. Koristkova B, et al. Differences between prescribed daily doses and defined daily doses of antiepileptics-therapeutic drug monitoring as a marker of the quality of the treatment. Int J Clin Pharmacol Ther 2006; 44: 438-442.
43. Eadie MJ,. Plasma antiepileptic drug monitoring in a neurological practice: a 25-year experience. Ther Drug Monit 1994; 16: 458-468.
44. Patsalos PN, et al. Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008; 49: 1239-1276.
45. Yukawa E,. Optimisation of antiepileptic drug therapy. The importance of serum drug concentration monitoring. Clin Pharmacokinet 1996; 31: 120-130.
46. Striano S, et al. Limited place for plasma monitoring of new antiepileptic drugs in clinical practice. Med Sci Monit 2008; 14: RA173-RA178.
47. Eadie MJ,. Therapeutic drug monitoring-antiepileptic drugs. Br J Clin Pharmacol 2001; 52 (Suppl. 1): 11S-20S.
48. Krasowski MD,. Therapeutic drug monitoring of the newer anti-epilepsy medications. Pharmaceuticals (Basel) 2010; 3: 1909-1935.
49. Johannessen SI, et al. Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? Clin Pharmacokinet 2006; 45: 1061-1075.